Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

Clinical trial NCT03985943 · COMPLETED

Trial details

NCT number: NCT03985943
Sponsor: Galderma R&D
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Moderate-to-Severe Atopic Dermatitis

Start date: 2019-06-27
Primary completion: 2021-12-29
Enrollment: 941

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.